Sage intends to present detailed results from the STATUS Trial at an upcoming medical meeting ... "Risk Factors" in our most recent Quarterly Report on Form 10-Q, as well as discussions of ...

The trial, which enrolled 147 participants, was designed to study the dose-response relationship of different doses of SAGE-324 for upper limb tremor for a three-month treatment period.

Sage. Sage 50 Accounting. NerdWallet Rating ... You’ll also have the opportunity to set up your chart of accounts, enter opening account balances and review your trial balance report.

Sage Therapeutics has slightly tweaked the primary endpoint for a phase 3 trial of the Biogen-partnered ... the change in its third-quarter earnings report Tuesday. RBC Capital Markets said ...